Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: Findings from a pilot study

Age and Ageing

Volumn 41, Issue 3, 2012, Pages 408-412

  Mukaetova Ladinska, Elizabeta B ^a   Abdel All, Zeinab ^a   Dodds, Steven ^a   Andra de, Joana ^a   Alves da Silva, Joaquim ^a   Kalaria, Raj N ^a   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

synuclein; Alzheimer's disease; APP; Biomarker; Clusterin; Elderly; Immunoglobulin; Platelet; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CLUSTERIN; IMMUNOGLOBULIN G; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MICROTUBULE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COGNITION; DISCRIMINANT ANALYSIS; ENGLAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULINS; LINEAR MODELS; MALE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE;

EID: 84860518949     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afr171     Document Type: Article

References (29)

1. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-46.
2. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011; 7: 263-9.
3. Lui JK, Laws SM, Li QX et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010; 20: 1233-42.
4. Schupf N, Zigman WB, Tang MX et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology 2010; 75: 1639-44.
5. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010; 67: 739-48.
6. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60: 958-64.
7. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer Disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010; 45: 53-6.
8. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost 2004; 30: 441-50.
9. Burbaeva GSH, Boksha IS, Tereshkina EB et al. Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. World J Biol Psychiatry 2006; 7: 75-81.
10. Roth M, Tym E, Mountjoy CQ et al. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
11. Walker MP, Ayre GA, Cummings JL et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000; 177: 252-6.
12. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988; 2: 271-84.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-13.
14. Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F et al. Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alphasynuclein in medial temporal lobe. Sci World J 2009; 9: 1463-75.
15. George JN. Platelet IgG: measurement, interpretation, and clinical significance. Prog Hemost Thromb 1991; 10: 97-126.
16. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129: 3042-50.
17. Mitchell MB, Buccafusco JJ, Schade RF et al. RAGE and Aβ immunoglobulins: relation to Alzheimer's disease-related cognitive function. J Int Neuropsychol Soc 2010; 16: 72-8.
18. Fjorback AW, Varming K, Jensen PH. Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest 2007; 67: 431-5.
19. Paleologou KE, Kragh CL, Mann DM et al. Detection of elevated levels of soluble alpha-synuclein oligomers in postmortem brain extracts from patients with dementia with Lewy bodies. Brain 2009; 132: 1093-101.
20. Borroni B, Colciaghi F, Corsini P et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol Sci 2002; 23: 207-10.
21. Vignini A, Sartini D, Morganti S et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: Evidence for peripheral marker. Int J Immunopathol Pharmacol 2011; 24: 529-34.
22. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011; 305: 1322-6.
23. Ijsselstijn L, Dekker LJ, Koudstaal PJ et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 2011; 10: 2006-10.
24. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-93.
25. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-9.
26. Neumann K, Farias G, Slachevsky A, Perez P, Maccioni RB. Human platelets tau: a potential peripheral marker for Alzheimer's disease. J Alzheimers Dis 2011; 25: 103-9.
27. Forlenza OV, Torres CA, Talib LL et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2011; 45: 220-4.
28. Trinder P, Rajaratnam G, Lewis M, Croft PP. Prophylactic aspirin use in the adult general population. J Public Health 2003; 25: 377-80.
29. Vartiainen E, Laatikainen T, Strandberg T, Salomaa V, Jousilahti P. Use of cholesterol lowering drugs could be improved further: results from the National FINRISK 2007 Study. Suomen Lääkärilehi 2009; 64: 4135-9.